Iteos TherapeuticsÂ Inc (ITOS)

Name: Iteos TherapeuticsÂ Inc (ITOS) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Iteos TherapeuticsÂ Inc (ITOS)

Stock Card

$10.15

$0.00 (0.00%)

As on 29-Aug-2025 09:30EDT

Market cap

$449 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

0.9

Div. Yield

0 %

Iteos TherapeuticsÂ Inc (ITOS) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 10.15 High: 10.15

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.3 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

0.5
Debt to Equity

0
Book Value

$--
EPS

$-4.7
Face value

--
Shares outstanding

44,205,400

6 Years Aggregate

CFO

$230.77 Mln

EBITDA

$164.12 Mln

Net Profit

$119.99 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Iteos TherapeuticsÂ Inc (ITOS)	32.2	0.4	0.9	-40.8	-23.6	-19.3	--
BSE Sensex^*	-9.1	-1.5	2.9	-3.6	5.9	6.0	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 29-Aug-2025 | *As on 01-Sep-2026 | #As on 26-Oct-2023

Company	2024	2023	2022	2021
Iteos TherapeuticsÂ Inc (ITOS)	-29.7	-43.9	-58.1	37.7
S&P Small-Cap 600	7.0	13.9	-17.4	25.3
BSE Sensex	8.1	18.7	4.4	22.0

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Iteos TherapeuticsÂ Inc (ITOS)

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of... T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts. As of August 28, 2025, iTeos Therapeutics, Inc. operates as a subsidiary of Concentra Biosciences, LLC. Read more

President, CEO & Director

Dr. Michel Detheux Ph.D.
President, CEO & Director

Dr. Michel Detheux Ph.D.
Headquarters

Watertown, MA
Website

https://www.iteostherapeutics.com

FAQs for Iteos TherapeuticsÂ Inc (ITOS)

What is the current share price of Iteos TherapeuticsÂ Inc (ITOS) Today?

The share price of Iteos TherapeuticsÂ Inc (ITOS) is $10.15 (NASDAQ) as of 29-Aug-2025 09:30 EDT. Iteos TherapeuticsÂ Inc (ITOS) has given a return of -23.64% in the last 3 years.

What is the current PB & PE ratio of Iteos TherapeuticsÂ Inc (ITOS)?

Since, TTM earnings of Iteos TherapeuticsÂ Inc (ITOS) is negative, P/E ratio is not available.
The P/B ratio of Iteos TherapeuticsÂ Inc (ITOS) is 0.91 times as on 29-Aug-2025, a 82 discount to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2024	-2.31	0.53
2023	-3.48	0.68
2022	7.65	1.12
2021	8.14	3.16
2020	-21.65	2.55

What is the 52 Week High and Low of Iteos TherapeuticsÂ Inc (ITOS)?

The 52-week high and low of Iteos TherapeuticsÂ Inc (ITOS) are Rs -- and Rs -- as of 01-Sep-2026.

What is the market cap of Iteos TherapeuticsÂ Inc (ITOS)?

Iteos TherapeuticsÂ Inc (ITOS) has a market capitalisation of $ 449 Mln as on 29-Aug-2025. As per SEBI classification, it is a Small Cap company.

Should I invest in Iteos TherapeuticsÂ Inc (ITOS)?

Before investing in Iteos TherapeuticsÂ Inc (ITOS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.